Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epitranscriptomics in the glioma context: A brief overview

  • Santamarina-Ojeda, Pablo
  • Fernández, Agustín F.
  • Fraga, Mario F.
This article belongs to the Special Issue Updates on Epigenetics of Brain Tumor., [Simple Summary] Epitranscriptomics, the study of chemical modifications in RNA, has emerged as a crucial field in cellular regulation, adding another layer to the established landscape of DNA- and histone-based epigenetics. A wide range of RNA modifications, including N6-methyladenosine, pseudouridine, and inosine, have been identified across nearly all RNA species, influencing essential processes such as transcription, splicing, RNA stability, and translation. In the context of brain tumors, particularly gliomas, specific epitranscriptomic signatures have been reported to play a role in tumorigenesis. Despite growing evidence, the biological implications of various RNA modifications remain poorly understood. This review offers an examination of the main RNA modifications, the interplay between modified and unmodified molecules, how they could contribute to glioma-like phenotypes, and the therapeutic impact of targeting these mechanisms., Epitranscriptomics, the study of chemical modifications in RNA, has emerged as a crucial field in cellular regulation, adding another layer to the established landscape of DNA- and histone-based epigenetics. A wide range of RNA modifications, including N6-methyladenosine, pseudouridine, and inosine, have been identified across nearly all RNA species, influencing essential processes such as transcription, splicing, RNA stability, and translation. In the context of brain tumors, particularly gliomas, specific epitranscriptomic signatures have been reported to play a role in tumorigenesis. Despite growing evidence, the biological implications of various RNA modifications remain poorly understood. This review offers an examination of the main RNA modifications, the interplay between modified and unmodified molecules, how they could contribute to glioma-like phenotypes, and the therapeutic impact of targeting these mechanisms., This research was funded by Carlos III Health Institute, co-funded by the European Regional Development Fund (FEDER) (grant PI21/01067 to M.M.F. and A.F.F.). Horizon Europe Program (HORIZON-HLTH-2022-STAYHLTH-01-two-stage, ref 101080219 to P.S.-O.), Spanish Association Against Cancer for funding under grant PRYGN235109FERN to M.M.F., and to the Asturias Government (PCTI) for co-funding under the 2018–2023/FEDER framework (grant IDI/2021/000077 to M.M.F. and A.F.F.). Additionally, we recognize the support from the EU TRANSCAN-3 initiative (JTC 2023) (ref. AC24/00163)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical evaluation of several polymeric micelles identifies Soluplus®-docetaxel as the most effective candidate in multiple glioblastoma models

  • German-Cortés, Júlia
  • Herrero, Raquel
  • Torroglosa, Natalia
  • Pumarola, Alexandra
  • Fischer-Albiol, Narine
  • Campos-Moreno, Sofia
  • Sabaté, Sofia
  • Alcina, Àngels
  • Mancilla, Sandra
  • Martínez-García, Belén
  • Llaguno-Munive, Monserrat
  • Díaz-Riascos, Zamira V.
  • Martins, Cláudia
  • Schwartz, Simó
  • Ferrer-Costa, Roser
  • Abasolo, Ibane
  • Sánchez-Gómez, Pilar
  • Sarmento, Bruno
  • Rafael, Diana
  • Andrade, Fernanda
Glioblastoma multiforme (GBM) is one of the most lethal cancers, with limited treatment options due to the blood-brain barrier (BBB), systemic toxicity, and treatment resistance. Nanomedicine offers potential solutions to these challenges. This study explores Pluronic® F127 and Soluplus®-based micelles as carriers for Lomustine, Gefitinib, and Docetaxel to determine the optimal system for GBM therapy. Micelles were physicochemically characterized and biologically validated using U87-MG and U251-MG GBM cell lines in 2D and 3D models, assessing internalization, safety, and therapeutic efficacy. Soluplus® micelles (SM) showed favorable properties for intravenous administration, including low polydispersity, efficient drug release in the tumoral microenvironment, minimal cell toxicity, and a BBB-crossing rate of 15 %. Among the drugs tested, Docetaxel showed the lowest IC50 values in both 2D cell models and demonstrated superior efficacy in 3D cultures when delivered by SM. Molecular analysis confirmed that SM-D impacts key GBM-related pathways, affecting markers like E-cadherin, EPCAM, L1CAM, or EGFR. In vivo, SM-D significantly reduced tumor mass and cancer cell density, showing a favorable safety profile compared to free Docetaxel, as evidenced by reduced weight loss and histological assessments. Overall, SM-D stands out as the most promising approach for GBM treatment, supporting the potential of nanomedicine in overcoming the barriers to effective glioblastoma therapy., This work was supported by the Networking Research Centre on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) which is financed by the Instituto de Salud Carlos III (ISCIII) with assistance from the European Regional Development Fund (ERDF) and by ReachGLIO project, funded by European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 964264. It was also partially funded by the Consolidated group from Generalitat de Catalunya (2021 SGR 01173). Diana Rafael was supported by Marie Skłodowska-Curie Actions (MSCA-PF ID 101107735). Fernanda Andrade was granted by the Fundación Científica de la Asociación Española contra el Cáncer (FAECC INVES211530DASI)., Peer reviewed